NEW YORK (GenomeWeb News) - Prolexys Pharmaceuticals announced today that it has received $20 million in a Preferred Series A1 round, which it will use to advance the clinical development of a molecule that has shown anti-tumor activity.
 
The funding round was led by Friedli Corporate Finance, whose chairman and CEO, Peter Friedli, is on Prolexys’ board.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.